Wancheng Liu

Prof. Wancheng Liu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
QCQiaomei Cai
Qiaomei Cai
CJChao Jing
Chao Jing
XWXudong Wang
Xudong Wang
XXXiangling Xing
Xiangling Xing
WLWancheng Liu
Wancheng Liu

20 January 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YHYingjian Huang
Yingjian Huang
YWYuqian Wang
Yuqian Wang
YZYunyue Zhen
Yunyue Zhen
WLWancheng Liu
Wancheng Liu
YWYan Wang
Yan Wang
QSQing Sun
Qing Sun

1 July 2025 in Genes & Diseases
Verified
Journal Article
Open access
YWYihong Wei
Yihong Wei
YXYing Xu
Ying Xu
YZYanqiong Zeng
Yanqiong Zeng
AZAmin Zhang
Amin Zhang
XXXiangling Xing
Xiangling Xing
WLWancheng Liu
Wancheng Liu

23 October 2025 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
YHYingjian Huang
Yingjian Huang
YWYihong Wei
Yihong Wei
XXXiangling Xing
Xiangling Xing
WLWancheng Liu
Wancheng Liu

9 May 2026 in Cell Communication and Signaling
Verified
Journal Article
Open access
YMYukang Ma
Yukang Ma
CMChi Ma
Chi Ma
AYAobo Yang
Aobo Yang
YCYiming Chen
Yiming Chen
JGJiajun Gao
Jiajun Gao
WLWancheng Liu
Wancheng Liu
The CUG-BP and Elav-like (CELF) family of RNA-binding proteins are key regulators of post-transcriptional gene expression, coordinating alternative splicing, mRNA stability, and translation. Although individual members, particularly CELF1 and CELF2, have been extensively characterized, a systematic, paralog-resolved integration of structural determinants, regulatory mechanisms, and disease relevance across all six CELF proteins remains limited. Here, we establish an integrative framework linking conserved RNA recognition motifs and divergent linker domains to context-dependent regulatory outputs, mediated by phosphorylation, nucleocytoplasmic dynamics, and RNA network interactions. We further highlight the neuron-enriched CELF3-CELF6 subfamily, consolidating emerging evidence that extends their roles beyond neural splicing into cancer-associated regulatory programs. Notably, we delineate functional divergence within the family, with CELF1 frequently acting as an oncogenic driver in contrast to the tumor-suppressive role of CELF2, while positioning less-characterized paralogs within this regulatory spectrum. Together, this work defines a unified structure-function-disease axis for CELF proteins and provides a conceptual framework for their prognostic and therapeutic exploitation. However, current CELF-targeted strategies remain largely preclinical and face key translational challenges, including paralog selectivity, off-target effects, and delivery barriers such as limited blood-brain barrier penetration. Accordingly, the most immediate clinical utility of CELF biology is likely to lie in biomarker development and patient stratification, rather than direct therapeutic intervention.

21 October 2026 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ZWZhixi Wei
Zhixi Wei
CMChi Ma
Chi Ma
JGJiajun Gao
Jiajun Gao
XZXinyi Zhang
Xinyi Zhang
YXYiping Xu
Yiping Xu
XXXiangling Xing
Xiangling Xing
Protein acylation comprises a diverse class of metabolite-responsive post-translational modifications that links cellular metabolic states to protein function and signaling. Beyond canonical acetylation, emerging acylation marks are dynamically controlled by acyl-donor availability and writer–eraser–reader systems, forming regulatory networks that reshape chromatin, metabolism, protein stability and localization, cytoskeletal dynamics, and immune responses. In cancer, dysregulated acylation enables tumor cells to adapt to metabolic and environmental stress, thereby promoting malignant progression, metastasis, immune escape, and therapeutic resistance. This Review examines the chemical and enzymatic principles of major protein acylations and integrates their roles across metabolic, epigenetic, signaling, and tumor-immune networks. We further discuss acylation-based biomarkers, patient stratification, pharmacological targeting, and mechanism-guided combination strategies, while highlighting challenges in modification specificity and clinical validation. Together, these advances position protein acylation as a regulatory interface between tumor plasticity and therapeutic response, providing a framework for biomarker-guided precision therapeutics.